Priscilla A. Furth, MD is a professor of oncology and medicine at Georgetown University. She worked as a research technician preparing slides for electron microscopy as an undergraduate student at Brown University and then, inspired by the work of Yale professor and prominent ASIP member Marilyn Farquhar, went on to graduate Yale University School of Medicine with a thesis entitled “The effects of chronic cadmium exposure on the rat kidney: correlated physiological and electron microscopic studies.” Subsequently, she completed internal medicine residency at Mount Sinai Medical Center in New York City, infectious disease fellowship at Harvard Medical School, a post-doctoral fellowship in the Laboratory of Tumor Virus Biology at NCI, NIH, and an Alexander von Humboldt fellowship at the Max Planck Institute of Biophysical Chemistry, Göttingen, Germany. She is a graduate of the 2014-2015 Class of the Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Program and from 2013-2020 she served as the Associate Dean for Faculty Development for Georgetown University Medical Center. At Georgetown she has been recognized for her mentorship with the 2020 Excellence in Mentorship Award (Biochemistry and Molecular Biology program) and 2018 Estelle Ramey Mentorship Award, and for her teaching as a 2019 Golden Apple Hoya Clinic Award Nominee and receipt of the 1989 Specialist Award (Family Medicine) at UMD. Her breast cancer research work was honored with the 2010 Georgetown Women in Medicine Outstanding Achievement Award and the 2007 Noel Soderberg Evans Award, Washington DC.
Dr. Furth’s research primarily focuses on use of human primary tissue and cells and genetically engineered mice to investigate breast cancer risk. A recent study leveraged primary conditional reprogrammed high risk human breast cells for characterization of transcriptional components of breast cancer risk while her current NIH funded work examines the impact of aging through reproductive senescence on initiation of mammary preneoplasia and response to anti-hormonal preventive agents utilizing genetically engineered mouse models with mammary targeted Esr1 and CYP19A1 expression. Trained in virology, Dr. Furth also has published work on HIV, papillomavirus, and SARS-CoV-2.
Dr. Furth has been a member of ASIP since 2003 and currently serves as the ASIP representative to the Intersociety Council on Pathology Informatics (ICPI) Board.